ReviewDiabetes & metabolic syndrome
Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges.
Review in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.Clinical and translational allergy · 2025Review
- COVID-19 Vaccines Breakthrough Infections and Adverse Effects Reported by the Birzeit University Community in Palestine.International journal of general medicine · 2024Article
- The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics.Molecular diagnosis & therapy · 2023Review
- Comparative Analysis of 198 SARS-CoV-2 Genomes from Iran and West Asia, February 2020 to December 2021.Iranian journal of pathology · 2023Article
- Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms.Molecular biology reports · 2022Review
- Nanoparticles for Coronavirus Control.Nanomaterials (Basel, Switzerland) · 2022Review
- A global survey in the developmental landscape of possible vaccination strategies for COVID-19.Clinical immunology (Orlando, Fla.) · 2022Review
- A novel G-quadruplex aptamer-based spike trimeric antigen test for the detection of SARS-CoV-2.Molecular therapy. Nucleic acids · 2021Article
- Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.Emerging microbes & infections · 2021Article
- COVID-19 Vaccination: What Challenges Are We Going to Face.Acta bio-medica : Atenei Parmensis · 2021Article
- COVID-19 vaccines and nanomedicine.International journal of dermatology · 2021Review
- Design of a novel multiple epitope-based vaccine: An immunoinformatics approach to combat SARS-CoV-2 strains.Journal of infection and public health · 2021Article
- Review of registered clinical trials for the treatment of COVID-19.Drug development research · 2021Review
- Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach.Epidemiologia (Basel, Switzerland) · 2021Article
- Article
- Tweet Topics and Sentiments Relating to COVID-19 Vaccination Among Australian Twitter Users: Machine Learning Analysis.Journal of medical Internet research · 2021Article
- Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?Risk management and healthcare policy · 2021Review
- Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19.Frontiers in molecular biosciences · 2021Review
- Repurposing of Drugs for SARS-CoV-2 Using Inverse Docking Fingerprints.Frontiers in chemistry · 2021Article
- Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies.Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe pandemic COVID-19 occurring due to novel emerging coronavirus-2019 (SARS-CoV-2) is severely affecting the worldwide public health, culture, economy and human social behaviour. Till date, there is no approved medicine/treatment to cure COVID-19, whereas, vaccine development efforts are going on high priority. This review aimed to provide an overview of prior art, recent advances, vaccine designing strategies, current scenario, opportunities and challenges related to development of coronavirus vaccine.
methodA literature survey was conducted using Scopus, PubMed and Google Scholar with the search key as: coronavirus vaccine, SARS vaccine, MERS vaccine and COVID-19 vaccine. Articles related to above search query were retrieved, sorted, analyzed and developed into an easy-to-understand review.
resultsThe genome phylogenetic analysis suggested that genomic sequence of SARS-CoV-2 is almost 80% similar to that of SARS-CoV, further both these viruses bind to same host cell receptor ACE-2. Hence it is expected that, previously available literature data about coronavirus vaccine designing may play crucial role in development of rapid vaccine against COVID-19. In view of this, the present review discuss (i) existing information (from 2003 to present) about the type of vaccine, antigen, immunogenic response, animal model, route of administration, adjuvants and current scenario for designing of coronavirus vaccine (ii) potential factors and challenges related to rapid development of COVID-19 vaccine.
conclusionIn conclusion, we discuss possible clues/ target sites for designing of vaccine against SARS-CoV-2 virus based on prior-art.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.